Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Public Citizen’s Health Group Changes Leadership, But Wolfe Remains On Prowl

Executive Summary

Wolfe steps down to become senior advisor but remains a vocal critic of the pharmaceutical industry and FDA, as his appearance at the Avandia advisory committee meeting demonstrated.

Advertisement

Related Content

Avandia Committee Gives Split Vote To Drug, But FDA Clear Winner
FDA Intellectual Bias Policy Takes Wolfe Off Contraceptives Safety Review
Cardiac Risks Of Propoxyphene Raced Out Of Control As FDA Moved For Immediate Withdrawal
REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues
Avandia Advisory Committee Re-Review Reflects Well On FDA
To Crestor’s Foe, FDA Says Toxicity Is Low, But DTC Ads Must Go

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS055410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel